Objective: The aims of this study were to compare the rate of completion of optimal debulking and/or 6 cycles of intraperitoneal (IP) chemotherapy in women with International Federation of Gynecologists and Obstetricians stage III/IV ovarian cancer undergoing neoadjuvant chemotherapy (NACT) versus primary surgery (PS) and to compare morbidity between these 2 groups. Methods: Ninety-six subjects with stage III/IV ovarian cancer who underwent either NACT or PS were identified. Data comparisons include rate of optimal debulking and completion rate of 6 cycles of IP chemotherapy. Other data collected included surgical times, length of stay, intensive care unit admissions, blood transfusions, bowel resections, major complications, and dose reductions. SigmaStat version 2.0 was used for statistical analysis. Results: Of the 96 subjects, 38 received NACT and 58 had PS. All 14 subjects with stage IV disease received NACT, and all experienced resolution of pleural effusion, based on computed tomographic imaging. Thirty-five (92%) of 38 NACT subjects versus 47 (81%) of 58 PS subjects were optimally debulked (P = 0.08). Thirty-six (95%) of 38 NACT subjects versus 37 (64%) of 58 PS subjects completed IP chemotherapy (P G 0.001). Length of stay was 3.26 (NACT) versus 5.08 (PS) days (P G 0.001). Intensive care unit admissions were 1 of 38 (NACT) versus 12 of 58 (PS) (P G 0.001). Bowel resections were done in 2 of 38 (NACT) versus 14 of 38 (PS) (P G 0.05). Duration of surgery was 96 minutes (NACT) versus 138 minutes (PS) (P G 0.001). A trend to fewer dose reductions occurred in NACT (1/38) versus PS (8/58) (P = 0.056). Conclusions: The NACT subjects were more likely to complete IP chemotherapy and had decreased length of stay, intensive care unit admissions, bowel resections, and duration of surgery. Both optimal debulking and dose reductions were numerically but not statistically associated with NACT versus PS. This likely reflects a relatively high overall rate of optimal debulking and low rate of dose reductions in these subjects and would require a larger group to determine significance.
I
n the United States, approximately 22,000 women will be diagnosed with ovarian cancer and 15,500 will die of the disease. 1 Standard therapy involves surgical staging followed by intravenous (IV) chemotherapy usually in the form of a platinum-based drug and paclitaxel. Although many women with International Federation of Gynecology and Obstetrics (FIGO) stage III/IV disease achieve a complete response to debulking surgery followed by IV chemotherapy, a majority of those will develop a recurrence and face a bleak probability of survival. 2, 3 Evidence from multiple randomized phase 3 trials has shown that patients with stage III disease have improved outcomes from optimal debulking followed by IV and intraperitoneal (IP) chemotherapy with regard to both progression-free survival and overall survival. 4, 5 Furthermore, a more recent study reported that survival was similar for patients with stage IIIC/IV disease randomized to neoadjuvant chemotherapy (NACT) followed by interval debulking compared with primary surgical debulking. 6 Intraperitoneal chemotherapy is not without its drawbacks. Intraperitoneal therapy is associated with increased rates of hematologic, neurologic, and gastrointestinal toxicities as well as pain and fatigue. 5 The best-documented regimens are complex and time consuming, often requiring the patient to come in for a treatment on 3 separate days of a traditional 3-to 4-week cycle, with each treatment lasting up to 3 hours. Further, administration of IP chemotherapy requires a reliable method of access to the peritoneal cavity, usually a surgically implanted catheter. The technique for placing catheters of this type is significantly different from that of IV catheters, requiring general anesthesia and at least 2 separate incisions. In most cases, the optimal timing for placement of an IP catheter is at the time of the initial staging and/or debulking procedure, necessitating planning for the possibility of IP chemotherapy use. As a result, catheter-related complications are not uncommon and are the primary reason that IP chemotherapy is discontinued. 5, 7 Although the National Cancer Institute released a clinical announcement in 2006 urging gynecologic oncologists to consider IP chemotherapy as a viable treatment option in optimally debulked patients, a survey to SGO (Society of Gynecologic Oncology) and ASCO (American Society of Clinical Oncology) members found that nearly 25% of respondents did not offer IP chemotherapy mostly because of concern over toxicity. 8, 9 This same survey suggested that the lack of a standard IP regimen had resulted in a variety of treatment modifications. 8 The rationale for this study was based on the principle that IP chemotherapy demonstrates a clinical advantage in the treatment of ovarian cancer. In fact, an ACOG committee opinion from 2008 states that the decision to use IV/IP chemotherapy should be individualized and may be an option for carefully selected patients with optimally debulked stage III ovarian cancer. 10 The aim of the current study was to demonstrate whether NACT decreases surgical morbidity, leaving patients more capable of tolerating IP chemotherapy, thus making it possible for them to complete a larger percentage of planned treatment. The primary aims included comparing the rates of optimal debulking and completion of 6 cycles of IP chemotherapy in subjects undergoing either NACTor primary surgery (PS). In addition, surgical outcomes were also examined.
MATERIALS AND METHODS
This study is a retrospective review of data that were gathered as part of an ongoing Quality Improvement program at the Harrington Cancer Center in Amarillo, TX (2002Y2009), and Tulane Cancer Center in New Orleans, LA (2009Y2011). Standardized, protocol-based programs for the treatment of ovarian cancer were created in both institutions with defined, measurable goals and Quality Reviews, which were carried out at predetermined intervals. This study grew out of those Quality Reviews and is a summary of the measured goals of the programs. In brief, all patients who initially presented with FIGO stage III ovarian, fallopian tube, or primary peritoneal carcinoma to these institutions were included in this analysis. Subjects defined as stage IV based on only the presence of malignant pleural effusions were also included. Other patients with stage IV metastases (eg, intrahepatic liver, central nervous system, or other extraperitoneal metastases) were not included in this study. Data on all subjects at these institutions were routinely collected and analyzed by research coordinators employed by the institutions for this purpose. The subjects gave consent for data collection with possible use in future research publications but not for specific research studies, and this specific research project was approved by local institutional review boards from both sites. Physicians involved in the treatment of these subjects included 4 gynecologic oncologists and 3 medical oncologists.
The subjects underwent either (a) primary surgical debulking or (b) NACTwith 3 doses of IV carboplatin, with an area under the curve of 6, and 175 mg/m 2 of paclitaxel, given every 3 weeks followed by surgical debulking. The decision to use NACT versus primary surgical debulking was left up to the treating physician, as per institutional protocol, and was based on multiple factors: patient age, performance status, medical comorbidities, history of other abdominal surgeries, and patient preference. The subjects who were optimally debulked underwent 6 doses of IP chemotherapy with the following treatment regimen: day 1, 3-hour IV infusion of 135 mg/m 2 of paclitaxel; day 2, 75 mg/m 2 of IP cisplatin; and day 8, 60 mg/m 2 of IP paclitaxel every 3 weeks (Fig. 1) . Those patients who did not achieve optimal debulking, either during PS or after NACT, were excluded from this analysis.
All ports were placed by 1 of 3 board-certified gynecologic oncologists with experience in performing the technique. Two catheter (port) types were used, including the Port-a-Cath IP type (Pharmacia-Deltic, St Paul, MN) and the PowerPort FIGURE 1. Treatment schematic.
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International Journal of Gynecological Cancer & Volume 24, Number 1, January 2014 (Bard Access Systems, Salt Lake City, UT). The technique for placing the ports is described in detail elsewhere. Briefly, the reservoirs were routinely placed in a subcutaneous pocket on the left lower chest wall, under the breast in the midclavicular line. If the left breast or the lower chest wall had undergone previous surgery, the catheter was placed in a similar position on the right lower chest wall. The tubing was tunneled under the skin to the umbilicus and then pulled into the peritoneal cavity through the abdominal wall muscle and fascia. Port placement was done either at the time of initial staging/debulking surgery or as a separate procedure.
All ports were accessed in an outpatient setting by registered nurses with training and accreditation in chemotherapy administration and specific instruction in IP catheter accession and management. The accession procedure and infusion processes are described in detail elsewhere. If the registered nurse was uncertain of the needle placement when attempting accession, the physician was notified and the patient underwent anteroposterior and lateral plain film x-rays for confirmation. Test infusions of 30 mL of sterile saline were given before all infusions. If the test infusion flowed easily, the standard infusion process was initiated with the patient in the supine position. The patients were observed throughout the infusion, with documentation of vital signs, patient symptoms, and needle placement at 15-minute intervals. If the patient moved from the supine position for any reason (eg, using the restroom), the needle placement was rechecked immediately upon return and documented.
The primary aim of this study was to compare the rates of optimal debulking and completion of 6 cycles of IP chemotherapy in subjects undergoing either NACT or PS. In addition, secondary aims involving surgical outcomes were also examined. The SigmaStat version 2.0 software was used for statistical analysis.
RESULTS
Ninety-six subjects underwent 109 cycles of IV NACT and 314 cycles of combined IV/IP chemotherapy. Patient characteristics including stage at diagnosis are shown in Table 1 . A majority of the patients in this study had stage IIIC (62.5%) and papillary serous (69%) histology. Of the 96 patients, 38 received NACT and 58 underwent PS. The baseline Ca-125 levels had a very wide range (84Y5034 U/mL) and did not differ by NACT versus PS. All 14 subjects with stage IV disease based on pleural effusions received NACT. There was a statistically significant difference (P G 0.001) between the number of stage IV patients in the NACT compared with that in the PS group.
Of the 38 patients in the NACT group, 35 patients (92%) were optimally debulked. Of the 3 who were not, 1 was stage IIIC and 2 were stage IV. In the PS group, 46 patients (81%) were optimally debulked. Of the remaining 12 patients, 8 were stage IIIC and 4 were stage IV.
As shown in Table 2 , the rate of optimal debulking between the NACT and PS groups was not statistically significant (P = 0.08). Of the patients with stage IIIC disease, 19 (95%) of those who received NACT were optimally debulked compared with 32 (80%) who underwent PS. None of the patients in the PS group with stage IV disease were optimally debulked as opposed to 86% in the NACT group. Furthermore, all stage IV patients in the NACT group experienced resolution of pleural effusions based on computed tomographic imaging.
A total of 81 patients were eligible to receive IP chemotherapy, as seen in Table 3 . Thirty-three of the 35 patients in the NACT group versus 30 of the 46 in the PS group were able to tolerate 6 cycles of IP chemotherapy. This difference was statistically significant. This outcome was similar when evaluating solely those patients with stage IIIC disease. The most common reason cited for discontinuing IP chemotherapy in this analysis was fatigue.
Of the patients completing 6 cycles of IP/IV chemotherapy, evaluation of secondary outcomes reflecting increased morbidity was also performed and is described in Table 4 . The mean length of stay (LOS) for the NACT group was 3.26 days compared with 5.08 days (P G 0.001), whereas the number of days in the intensive care unit (ICU) was 0.026 in the NACT group and 0.327 in the PS group (P = 0.008). The number of bowel resections, 2 in the NACT versus 14 in the PS, was found to be statistically significant (P G 0.05), as was the duration of surgery, 96 minutes for the NACT and 138 minutes for the PS (P G 0.001). The remaining secondary outcomes were not statistically significant; however, the P value for number of dose reductions was 0.056, with the NACT group experiencing fewer reductions than the PS group (1 vs 8).
DISCUSSION
In this retrospective study, we found that the subjects receiving NACT were more likely to complete 6 cycles of IP chemotherapy. The patients receiving NACT were also more likely to have decreased LOS, ICU admissions, bowel resections, and duration of surgery. These secondary outcomes are generally assumed to be associated with decreased morbidity. In particular, decreased duration of surgery leads to less time under general anesthesia and its associated complications. 11 We did not find a statistical significance in the rates of optimal debulking between the NACT and PS groups. In addition, although the number of dose reductions was not statistically significant, a P value of 0.056 suggests a possible relationship that could not be determined given the sample size. We postulate that NACT seems to be associated with a trend toward more frequent optimal debulking and less dose reductions. The inability of this study to show a statistically significant difference between the NACT and the PS likely reflects a relatively high overall rate of optimal debulking and low rate of dose reductions in these subjects. Institutions with committed IP programs typically achieve similar levels of optimal debulking and low rates of dose reduction. 12 Thus, a much larger study would likely be required to determine the significance of these differences in this setting.
The limitations of this study therefore include its retrospective study design and relatively small sample size. Furthermore, one must account for preferred physician practices. The physician's clinical judgment was used to decide who received which treatment, and this, in turn, is based on provider preferences. In addition, there is minimal information on functional status, which would be useful and clinically relevant if there was a difference between the 2 groups.
A goal of this study was to identify the benefits of NACT and improve the selection criteria for NACT versus primary debulking surgery, based on the assumption that patients will benefit from the opportunity to receive a complete course of IP chemotherapy. We conclude that NACT may be a viable option before cytoreductive surgery for FIGO stage IIIC/IV disease in this setting. Neoadjuvant chemotherapy allowed more patients to complete a planned course of 6 doses of IP chemotherapy, which, in turn, has been shown to be associated with a survival advantage. Neoadjuvant chemotherapy may also increase the likelihood of optimal debulking; however, more robust studies would be needed to determine statistical significance. Future studies could potentially limit participants to those with stage IIIC/IV (pleural effusion only) disease while randomizing them to NACT versus PS. Data on functional status may reveal subpopulations that benefit more than others from NACT. For example, poor surgical candidates including the elderly or those with comorbidities may see their status improved by NACT to the point that they could tolerate debulking surgery. The standardization of an IP chemotherapy regimen is also imperative in making this a palatable option for physicians not providing the service because of concern over toxicities or uncertainty about dosing.
